Kyowa Kirin Co Ltd
TSE:4151
Net Margin
Kyowa Kirin Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JP |
|
Kyowa Kirin Co Ltd
TSE:4151
|
1.2T JPY |
12%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
696.3B USD |
24%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
370.4B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
199.9B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
181.5B CHF |
23%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
156.8B GBP |
13%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
193.6B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
162.4B USD |
-126%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
112B EUR |
13%
|
Kyowa Kirin Co Ltd
Glance View
Kyowa Kirin Co., Ltd. stands as a notable presence in the global pharmaceutical landscape, having evolved from its roots in Japan into a significant force in medical innovation. This company, originally established from the merger of Kyowa Hakko Kogyo and Kirin Pharma, focuses on the development and commercialization of biopharmaceuticals that tackle complex medical conditions, primarily within the fields of oncology, nephrology, immunology, and neurology. With a strategy deeply rooted in research and development, Kyowa Kirin harnesses its proprietary antibody technologies and innovative approaches to deliver therapeutic solutions, fostering partnerships that expand its impact and reach. Their commitment to scientific progress is supplemented by a robust pipeline of investigational drugs, demonstrating their dedication to addressing unmet medical needs. Kyowa Kirin operates primarily on a business model that derives revenues from the successful commercialization of its pharmaceutical products. The company navigates the delicate balance between high-stakes investment in R&D and the potential high rewards that come from developing effective new treatments. By consistently bringing innovative therapies to market, they generate revenue through direct sales, collaborations, and licensing agreements within both domestic and international spheres. Additionally, their strategic alliances with biotech firms and research institutions globally enable them to enhance their R&D capabilities, ensuring a steady flow of new drugs that sustain their growth and solidify their competitive edge in the highly regulated and competitive pharmaceutical sector.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Kyowa Kirin Co Ltd's most recent financial statements, the company has Net Margin of 12.1%.
You don't have any saved screeners yet